RECRUITING

Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress

Talk to us

Conditions

Li-Fraumeni SyndromeTP53 Gene MutationHereditary Cancer SyndromeClonal HematopoiesisMosaicismTP53 Gene Mutation (Variant)

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome (LFS), a hereditary cancer risk condition, and TP53 variants found in the blood for other reasons (e.g. ACE/CHIP and mosaicism).

Official Title

Li-Fraumeni & TP53: Understanding and Progress (LiFT UP)

Quick Facts

Study Start:2020-09-15
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04541654

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Individuals with a TP53 pathogenic or likely pathogenic variant identified in blood or saliva,
  2. * Individuals with variants of uncertain significance in TP53 may be eligible at the PI's discretion,
  3. * Blood relatives of individuals with a TP53 variant, who may be presumed obligate carriers or healthy controls,
  4. * Individuals who meet Classic or Chompret LFS criteria whether or not they have a TP53 gene variant,
  5. * Individuals may enroll their deceased relatives in the study.
  6. * Individuals with a known TP53 variant that is not LFS, but rather ACE, CHIP, or mosaicism.
  7. * Individuals participating in other LFS studies can still enroll in LiFT UP. Investigators may be collaborators.
  1. * Individuals who decline to sign consent
  2. * Individuals who are unable to give consent or assent and are without a designated healthcare proxy

Contacts and Locations

Study Contact

Judy E Garber, MD, MPH
CONTACT
617-632-5770
jegarber@partners.org
Sophie Cahill, BS
CONTACT
617-632-4795
Sophie_Cahill@DFCI.HARVARD.edu

Principal Investigator

Judy E Garber, MD, MPH
PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute

Study Locations (Sites)

Boston Children's Hospital
Boston, Massachusetts, 02115
United States
Brigham and Women's Hospital
Boston, Massachusetts, 02215
United States
Judy E. Garber
Boston, Massachusetts, 02215
United States

Collaborators and Investigators

Sponsor: Dana-Farber Cancer Institute

  • Judy E Garber, MD, MPH, PRINCIPAL_INVESTIGATOR, Dana-Farber Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-09-15
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2020-09-15
Study Completion Date2025-12-31

Terms related to this study

Keywords Provided by Researchers

  • Li-Fraumeni Syndrome
  • TP53 Gene Mutation (Variant)
  • Hereditary Cancer Syndrome
  • Clonal Hematopoiesis
  • Mosaicism

Additional Relevant MeSH Terms

  • Li-Fraumeni Syndrome
  • TP53 Gene Mutation
  • Hereditary Cancer Syndrome
  • Clonal Hematopoiesis
  • Mosaicism